IP Library Granted Patent US 7,041,502
Granted Patent B2
US 7,041,502 · App. 10/164,078 · Granted May 9, 2006

Isolated peptides which bind to HLA-B18 molecules and uses thereof

Assignee: Ludwig Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,041,502
App. No.
10/164,078
Granted
May 9, 2006
Kind
B2
Abstract

A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.

Claims (18)

1. An isolated cytolytic T lymphocyte which recognizes complexes of HLA-B18 molecules and the peptide consisting of the first 10 amino acids of SEQ ID NO: 1, wherein said isolated cytolytic T lymphocyte does not recognize any other complexes of MHC molecules and peptides.

2. A method for determining if a subject who is HLA-B18 and is suffering from a cancer whicb expresses MAGE-3, comprising:

incubating a sample of cells taken from said subject with an immunologically active agent which recognizes complexes of an HLA-B18 molecule and the first 10 amino acids of SEQ ID NO: 1, and

determining interaction between said immunologically active agent and said cells in said sample as a determination of cancer in said subject.

3. The method of claim 2 , wherein said immunologically active agent is a cytolytic T lymphocyte.

4. The method of claim 3 , comprising determining lysis of cells by said cytolytic T lymphocyte.

5. The method of claim 3 , comprising measuring tumor necrosis factor release by said cytolytic T lymphocyte.

6. The method of claim 2 , wherein said immunologically active agent is an antibody.

7. An isolated peptide consisting of from about 11 to about 40 amino acids found in the amino acid seciwence of MAGE-3, wherein the amino acid sequence of said peptide consists of

MEVDPIGHLY (amino acids 1–10 of SEQ ID NO:1)

concatenated to from 1 to about 30 additional amino acids at Met or Tyr, wherein said peptide is processed by an antigen presenting cell to a peptide consisting of

MEVDPIGHLY (amino acids 1–10 of SEQ ID NO:1).

8. The isolated peptide of claim 7 , consisting of the amino acid sequence set forth in SEQ ID NO: 1.

9. An isolated nucleic acid molecule consisting of a nucleotide sequence which encodes the isolated peptide of claim 7 .

10. An isolated nucleic acid molecule which consists of a nucleotide sequence which encodes MEVDPIGHLY(amino acids 1–10 of SEQ ID NO:1).

11. A composition comprising

(i) isolated peptide MEVDPIGHLY(amino acids 1–10 of SEQ ID NO:1), and

(ii) at least one additional isolated peptide as set forth in SEQ ID NOS: 1–28, 32, 34, and 35.

Assignments (2)
CORRECTION TO THE SPELLING OF INVENTOR VAN DER BRUGGEN Recorded Jan 21, 2003
From: PANICHELLI, CHRISTOPHE; BILSBOROUGH, JANINE; SCHULTZ, ERWIN; BOON-FALLEUR, THIERRY; VAN DER BRUGGEN, PIERRE
To: LUDWIG INSTITUTE FOR CANCER RESEARCH
Reel/Frame 013696/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2002
From: PANICHELLI, CHRISTOPHE; BILSBOROUGH, JANINE; SCHULTZ, ERWIN; BOON-FALLEUR, THIERRY; VAN DE BRUGGEN, PIERRE
To: LUDWIG INSTITUTE FOR CANCER RESEARCH
Reel/Frame 013272/0049 →
Continuity (1)
Related Publication 20030228325A1 · Dec 11, 2003